Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
LG Chem will receive totaling up to $95.5 million for the China rights
The current ruling will assure the safety of the use of Ranitidine for Indian patients
EC grants conditional marketing authorization based on the EFFISAYIL trial
The yoga protocol included gentle and restorative yoga postures(asana) with regular periods of relaxation and pranayama
They also released the Operational Guidelines for Wellness activities at AB-HWCs
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Subscribe To Our Newsletter & Stay Updated
